Reoperation Rate in Breast-Conserving Surgery Using Confocal Histolog® Scanner for Intraoperative Margin Assessment
- Conditions
- Breast-Conserving SurgeryBreast Cancer - Ductal Carcinoma in Situ (DCIS)
- Interventions
- Device: Histolog Scanner
- Registration Number
- NCT05946759
- Lead Sponsor
- SamanTree Medical SA
- Brief Summary
This PMPF study is proposed to evaluate in real life the reoperation rates (ROR) of breast cancer and/or DCIS surgery when including the use of the HLS in the context of breast lumpectomy margin assessment.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 54
- Adult female Subject ≥18 years old.
- Subject Scheduled for breast conserving surgery of invasive and/or in-situ ductal carcinoma.
- Subject is able to read, understand and sign the informed consent.
- Subject previously treated for ipsilateral breast cancer and/or ductal carcinoma in situ surgery.
- Subject with previous radiotherapy of the ipsilateral breast.
- Subject with multicentric/multilateral breast cancer.
- Subject with planned mastectomy, tumor-adapted breast reduction.
- Subject with pre-surgical/ preoperative neo-adjuvant treatment.
- Subject is pregnant/ lactating.
- Participation in any other clinical study that would affect data acquisition.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Prospective Histolog Scanner 50 prospective subjects
- Primary Outcome Measures
Name Time Method Reoperation Rate 2-30 days post Breast Surgery Differences in the rate of reoperation due to cancer positive margins
- Secondary Outcome Measures
Name Time Method Change in hospital cost with or without IVD device and accessories [Economic Impact] 30 days post surgery date To evaluate the economic impact for the hospital/payer of the reoperation rate
System Usability Scale (SUS) of the IVD device and accessories [Usability] Only during the time of the breast surgery To survey usability of the HLS and accessories when used intraoperatively
Incidence of adverse device effects [Safety] Only during the time of the breast surgery Incidence of adverse device effects during surgery
Margin status of intraoperative specimen vs. postoperative pathology assessment [Clinical Performance] 0-30 days post Breast Surgery To observe real life clinical performance of the HLS and accessories when used intraoperatively
Trial Locations
- Locations (1)
St. Vincenz-Krankenhaus GmbH, Frauenklinik St. Louise
🇩🇪Paderborn, Germany